Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D
Advanced Malignant Cancer
DRUG: SHR-2022 Injection
Incidence of adverse events, up to 3 years|Severity of adverse events, up to 3 years|MTD, up to 3 years|RP2D, up to 3 years
Time to maximum concentration (Tmax), up to 3 year|Maximum concentration (Cmax), up to 3 year|Receptor Occupancy（OR） of SHR-2022, up to 3 year|Anti-drug antibody (ADA) of SHR-2022, up to 3 year|Objective response rate (ORR), up to 3 year
To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D